Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB versus RELAFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB versus RELAFEN.
IBU-TAB vs RELAFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Nabumetone is a nonacidic nonsteroidal anti-inflammatory drug (NSAID) that is a prodrug, rapidly metabolized to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which inhibits cyclooxygenase (COX) and thereby prostaglandin synthesis.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
1000 mg orally once daily, or 500 mg twice daily. Maximum dose 2000 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain.
Terminal elimination half-life approximately 24 hours (range 20-30 hours), allowing once-daily dosing.
Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%.
Primarily renal (90% as metabolites, ~5% unchanged); biliary/fecal minor (<5%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)